^
    1d
    A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=1800, Recruiting, Shanghai JMT-Bio Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • epirubicin • anbenitamab (KN026)
    1d
    HERIZON-BTC-302: Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer (clinicaltrials.gov)
    P3, N=286, Active, not recruiting, Jazz Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • cisplatin • Imfinzi (durvalumab) • gemcitabine • Ziihera (zanidatamab-hrii)
    1d
    A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    trastuzumab brengitecan (BL-M07D1)
    1d
    A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=596, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • trastuzumab brengitecan (BL-M07D1)
    2d
    Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer. (PubMed, Br J Cancer)
    [225Ac]Ac-Macropa-pertuzumab-PEG6-DM1 is more potent than pertuzumab-PEG6-DM1 against trastuzumab or T-DM1-resistant BC necessitating clinical investigation.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • EGFR positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine)
    2d
    Prediction of Outcomes of Brain Irradiation in Correlation with Molecular Subtypes in Patients with Metastatic Breast Cancer. (PubMed, Asian Pac J Cancer Prev)
    This study identifies key prognostic factors influencing survival in breast cancer patients with BM and proposes a scoring system to guide radiotherapy decisions. Molecular subtypes, metastatic burden, and clinical characteristics significantly affect outcomes, with HER2-positive and triple-negative subtypes showing the poorest survival. The system provides a structured approach for treatment selection, though further validation is needed to ensure its accuracy and clinical utility in personalized radiotherapy planning.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    2d
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. (clinicaltrials.gov)
    P3, N=400, Recruiting, Pfizer
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    everolimus • fulvestrant • exemestane • prifetrastat (PF-07248144)
    3d
    ARM-LIFE: Impact of the ARM Technique on the Prevention of Lymphedema After Axillary Lymphadenectomy: A Multicenter Randomized Clinical Trial (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, Hospital Universitari de Bellvitge
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    3d
    Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSLN (Mesothelin) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    HER-2 positive • HER-2 expression
    |
    cyclophosphamide • fludarabine IV
    4d
    A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy (clinicaltrials.gov)
    P=N/A, N=30, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • EGFR positive